Shares of Johnson & Johnson (NYSE: JNJ) experienced a decline of 2.3% during trading on Thursday, dropping to a low of $235.93 before closing at $239.65. Approximately 9,335,018 shares exchanged hands, maintaining a trading volume consistent with its average daily volume of 9,320,393 shares. The stock had previously closed at $245.30, reflecting a notable shift in market sentiment.
Recent Analyst Ratings and Market Impact
Analysts have been actively evaluating Johnson & Johnson, leading to various updates on their ratings. On December 11, BMO Capital Markets reaffirmed an “outperform” rating for the company. Meanwhile, JPMorgan Chase & Co. raised its price target from $225.00 to $250.00 while maintaining a “neutral” rating.
In a similar vein, Guggenheim increased its price target from $227.00 to $240.00 and assigned a “buy” rating. Sanford C. Bernstein also raised its target price from $208.00 to $225.00 with a “market perform” rating. Lastly, Rothschild & Co Redburn adjusted its target from $180.00 to $210.00, maintaining a “neutral” stance.
Currently, one analyst rates the stock as a Strong Buy, while seventeen have assigned Buy ratings and nine have given it a Hold rating, according to MarketBeat data. This results in a consensus rating of “Moderate Buy” with a projected price target of $234.87.
Financial Overview and Dividend Announcement
Johnson & Johnson holds a market capitalization of $579.75 billion and boasts a price-to-earnings ratio of 21.77. The company has a current ratio of 1.03 and a debt-to-equity ratio of 0.48. Its fifty-day moving average price stands at $228.36, while the 200-day moving average is $204.01.
In its most recent quarterly earnings report released on January 31, Johnson & Johnson reported earnings per share (EPS) of $2.46 and revenue of $24.28 billion. The company achieved a return on equity of 33.04% and a net margin of 28.46%. Analysts forecast that Johnson & Johnson will post an EPS of $10.58 for the current fiscal year.
Additionally, the firm has declared a quarterly dividend of $1.30, payable on March 10, 2024, to stockholders of record on February 24. This dividend represents an annualized payout of $5.20, yielding 2.2%, with the ex-dividend date also set for February 24. The company’s dividend payout ratio stands at 47.06%.
In recent insider transactions, Timothy Schmid, Executive Vice President, sold 1,322 shares at an average price of $245.66, totaling approximately $324,762.52. Following this transaction, Schmid holds 25,447 shares valued at around $6,251,310.02. Another executive, Vanessa Broadhurst, sold 6,197 shares at an average price of $243.39, amounting to roughly $1,508,287.83. Overall, insiders have sold a total of 30,142 shares valued at $7,360,528 in the last three months.
Institutional investors hold a significant portion of the company’s stock, with 69.55% currently owned by hedge funds and large investors. Recent adjustments include Brighton Jones LLC, which increased its holdings by 13.9% during the fourth quarter, and United Bank, which raised its stake by 110.7% in the first quarter.
Company Background
Founded in 1886 by the Johnson family, Johnson & Johnson is headquartered in New Brunswick, New Jersey. The multinational healthcare company develops, manufactures, and markets a broad range of products across pharmaceuticals, medical devices, and consumer health sectors. Its pharmaceuticals business operates mainly under its Janssen research and development organization, focusing on prescription medicines in areas such as immunology, infectious diseases, oncology, and neuroscience.
As the company navigates the complexities of the healthcare market, the recent fluctuations in its stock price and ongoing analyst evaluations will be closely watched by investors and market analysts alike.
